Search

everythinglearnresearchcommunity

for

Search:↓

Hair cloning is unlikely to be available soon, with estimates ranging from 10 to 20 years away. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options.

A 21-year-old is using Dualgen-5R (minoxidil and tretinoin) and weekly dermarolling to address hair loss, noticing some progress after three months. They plan to add an anti-androgen like RU58841 or Kx826 for better long-term results.

The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The user is experiencing hair loss and is using 2% ketoconazole shampoo, Minoxidil, and Finasteride. They are considering switching from Finasteride to Dutasteride, but others suggest waiting due to a possible shedding phase.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user is experiencing one-sided diffuse thinning and has been using finasteride and liquid minoxidil for 4-5 years with minimal results. They are considering whether to save for a hair transplant or address scalp sensitivity and irritation first.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

Focus on scalp health, not just DHT suppression, is crucial for hair regrowth. Effective treatments include Hair Restoration shampoo, LLLT laser cap, microneedling, and topical finasteride.

An 18-year-old is considering using minoxidil for thinning hair at the corners and is cautious about starting finasteride. They are also seeking style advice, with suggestions that fringes can help cover thinning areas.

The conversation discusses hair regrowth and miniaturization, with the user transitioning to oral dutasteride and oral minoxidil, and occasionally using topical minoxidil. The user observes baby hairs near the hairline but less on the scalp, indicating possible regrowth and shedding.

User seeks advice for regrowing temples, currently using Fin, oral Min, and dermarolling. Suggestions include improving scalp environment and considering RU58841 or dutasteride.

A 17-year-old is experiencing hair shedding and is concerned about a receding hairline, using hair products like powder and sea salt spray. Advice given includes maintaining good nutrition, ensuring hair products don't build up, and considering further resources if worried.

A 19-year-old male experienced side effects from finasteride and stopped using it, continuing with topical minoxidil. He plans to consult a dermatologist for further advice and is considering topical dutasteride as an alternative.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The user is experiencing hair loss and confusion over conflicting medical advice, with treatments including minoxidil, finasteride, and topical corticosteroids. They are unsure about the necessity of a biopsy and the timing of using minoxidil, while also considering the impact of potential androgenetic alopecia and telogen effluvium.

A 32-year-old shares 2-month progress using oral finasteride, topical minoxidil, and weekly derma stamping for hair loss, noting early improvements and no side effects. Encouragement is given for continued progress.

An 18-year-old is experiencing positive hair regrowth results using 2.5mg minoxidil, 0.5mg finasteride daily, and dermarolling twice a week. They are satisfied with the progress and hope for continued improvement.

The conversation emphasizes the importance of starting hair loss treatment early, using options like minoxidil, finasteride, RU58841, essential oils, and dermarolling, and encourages leaving the hair loss subreddit once treatment begins to avoid stress and obsession. Users shared personal success with finasteride and the motivation to start treatment to prevent future regret.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

A 26-year-old is considering switching from a finasteride and minoxidil blend to using dutasteride and minoxidil separately, with concerns about shedding and dosage changes. They are exploring options for sourcing and considering using ketoconazole shampoo to manage dryness.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A 23-year-old is concerned about hair loss and is considering starting minoxidil and finasteride to maintain their current hair. They are unsure whether to begin treatment now or wait to confirm if hair loss is occurring.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.